Sarah Atkins
Nurse Practitioner · Little Rock, ARNPI 1871139394
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 702 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 36.4% of the total. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 702 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Johnson & Johnson$1K
- Intercept Pharmaceuticals, Inc.$614
- Ironwood Pharmaceuticals, Inc$590
- Regeneron Healthcare Solutions, Inc.$485
- plus $4K from 29 others
What the payments were for
- Food & beverage$12,29599%
- Education$1151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 239 | $4,520 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 84 | $1,212 |
| Johnson & Johnson | 59 | $1,176 |
| Intercept Pharmaceuticals, Inc. | 26 | $614 |
| Ironwood Pharmaceuticals, Inc | 73 | $590 |
| Regeneron Healthcare Solutions, Inc. | 16 | $485 |
| Aimmune Therapeutics, Inc. | 30 | $465 |
| Gilead | 17 | $450 |
| Enterra Medical, Inc. | 9 | $428 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $372 |
| QOL Medical, LLC | 10 | $256 |
| Phathom Pharmaceuticals, Inc. | 29 | $232 |
| Ardelyx, Inc. | 7 | $197 |
| Merck | 10 | $196 |
| Nestle Healthcare Nutrition Inc. | 18 | $194 |
| Madrigal Pharmaceuticals | 6 | $168 |
| Janssen Scientific Affairs, LLC | 3 | $138 |
| Pfizer | 8 | $137 |
| Ipsen Biopharmaceuticals, Inc | 5 | $93 |
| Redhill Biopharma Inc. | 3 | $56 |
| Ferring Pharmaceuticals Inc. | 4 | $51 |
| Medtronic | 2 | $45 |
| Lilly USA, LLC | 2 | $41 |
| Sanofi | 2 | $39 |
| Novo Nordisk | 2 | $35 |
| Vivus LLC | 2 | $32 |
| UCB, Inc. | 2 | $29 |
| Axonics, Inc. | 2 | $26 |
| Braintree Laboratories, Inc. | 2 | $26 |
| Endogastric Solutions, Inc | 1 | $24 |
| Phadia US Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Amgen | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Bristol Myers Squibb | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,410 in reported general payments places this provider in the 95th percentile of 697 nurse practitioner providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 24 | $662,231 |
| XifaxanRifaximin | 43 | $146,877 |
| CreonLipase/Protease/Amylase | 28 | $117,290 |
| ZenpepLipase/Protease/Amylase | 19 | $100,314 |
| LinzessLinaclotide | 56 | $46,671 |
| MotegrityPrucalopride Succinate | 16 | $10,214 |
| VoqueznaVonoprazan Fumarate | 14 | $8,435 |
| Lubiprostone | 24 | $2,104 |
| Colestipol Hcl | 26 | $1,351 |
| Omeprazole | 100 | $1,163 |
| Ondansetron OdtOndansetron | 45 | $1,018 |
| Pantoprazole Sodium | 119 | $891 |
| Sucralfate | 15 | $581 |
| ConstuloseLactulose | 14 | $332 |
| Lactulose | 17 | $287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,176 | $662,23124 claims |
| AbbVieCreon, Linzess | $4,520 | $163,96084 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,212 | $146,87743 claims |
| Aimmune Therapeutics, Inc.Zenpep | $465 | $100,31419 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $372 | $10,21416 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $232 | $8,43514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 697 nurse practitioner providers in Arkansas.
Other nurse practitioner in Little Rock
- Iris KennedyLittle Rock$22K
- Julia PonderLittle Rock$21K
- Olivia CoxLittle Rock$14K
- Lauren ByersLittle Rock$8K
- Suzanne BroadwayLittle Rock$6K
- Natalie ByarsLittle Rock$6K
- Kristie CronkhiteLittle Rock$5K
- Mary GuellLittle Rock$5K
- Danielle LeeperLittle Rock$4K
- Leigh JohnsonLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.